The Hill: Washington must help patients choose, not dictate their care


Over a decade ago, I founded the Partnership to Improve Patient Care with a basic principle: Patients are best served when they are informed and empowered to decide which care options are best for them; they are poorly served when policymakers in Washington dictate which options are best.

Real Clear Health: Congress Moves to Import Discriminatory Health Policies


Healthcare costs seem to be a constant discussion point both in Washington and in our state capitals. Policymakers are on a quest for a silver bullet that they can trumpet as a win to constituents, but this debate is complex, and nuanced; and will have enormous ramifications for American patients, like my daughter, Marissa, who lives with sickle cell disease and who has a new lease on life from innovative treatments.

Morning Consult: Drug Pricing Policy Must Prioritize Patients


The drug pricing debate continues to rage on, both at the federal level – look to H.R. 3, seen in the House in 2019 that imported foreign pricing models, which a recent Congressional Budget Office report acknowledges relied on the Quality-Adjusted Life Year to score savings – and in the states, like in my home state of Massachusetts, where our Health Policy Commission has signed a contract with the Institute for Clinical and Economic Review to develop a…

Washington State Wire: SB 5020 Includes Group Known for Discriminatory Practices


The cost of health care is high. Too high. There is discussion by federal and state lawmakers about policies to lower costs to protect patients and their families. I applaud the intent, but, as the parent of a child with cystic fibrosis (CF) and the leader of a patient advocacy organization, I believe they are missing the mark.

InsideSources: Socialized Medicine and Rationing COVID Care Defy American Principles


As an American, I’m proud to live in a country that is built on the inalienable rights of its citizens and the sacred principle that “all men are created equal.” However, as the parent of a child with spinal muscular atrophy (SMA) Type 1, I’ve realized that when it comes to our healthcare system — from rationing of care to the push to adopt drug policies from socialist nations — we don’t always live up…

Bloomberg Law: Lost Work, ER Visits Urged in Drug Panel’s Migraine Analysis


Lost work days and time spent in emergency rooms should have weighed more heavily in an analysis of migraine medicines by an influential advisory board, advocates said. The Institute for Clinical and Economic Review, a nonprofit that analyzes whether a drug’s outcome for patients justifies its price tag, can sway insurers’ decisions on drug coverage. It recently determined that Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and rimegepant—a Biohaven drug still being considered for approval by the…

Politico: ICER Revises Migraine Report, But Advocacy Groups Still Not Satisfied


The Institute for Clinical and Economic Review revised its previous assessment of two new migraine drugs, determining that they meet its long-term cost-effectiveness thresholds — after previously ruling the cost of the medicines was too high. The final evidence report concluded that Allergan’s Ubrelvy, which costs $4,896 a year, and Biohaven’s rimegepant meet the cost-effectiveness threshold.

Inside Health Policy: Advocacy Groups Push ICER To Reevaluate Migraine Drug Analysis


Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors. The advocacy groups expect the cost-effectiveness rating of the three drugs would increase further using that framework.